Prosecution Insights
Last updated: April 19, 2026
Application No. 17/636,003

MITOCHONDRIAL MODULATION TO IMPROVE METABOLIC SYNDROME DURING AGING

Non-Final OA §102
Filed
Feb 16, 2022
Examiner
VAJDA, KRISTIN ANN
Art Unit
1622
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Shanghai Jiao Tong University
OA Round
3 (Non-Final)
84%
Grant Probability
Favorable
3-4
OA Rounds
2y 0m
To Grant
95%
With Interview

Examiner Intelligence

Grants 84% — above average
84%
Career Allow Rate
1331 granted / 1581 resolved
+24.2% vs TC avg
Moderate +10% lift
Without
With
+10.5%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 0m
Avg Prosecution
36 currently pending
Career history
1617
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
11.2%
-28.8% vs TC avg
§102
27.6%
-12.4% vs TC avg
§112
33.6%
-6.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1581 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1, 6-12 and 17-20 are pending in the instant application. Claims 10-12 and 17-20 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to non-elected subject matter. Claims 1 and 8 are rejected. Claims 6, 7 and 9 are objected. Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on March 9, 2026 has been entered. Response to Amendment and Arguments/Remarks The amendment and arguments/remarks filed on March 9, 2026 have been fully considered and entered into the application. With regards to the 35 U.S.C. 112(b) rejection over claims 1, 6 and 7, the grounds for rejection are moot in view of Applicant’s amendment and the rejection has been withdrawn. With regards to the 35 U.S.C. 112(b) rejection over claim 9, Applicant argues “the primary amines of HG1a-13 to -18 are positively charged at pH 7.4, the pH at which the charge of the present molecules should be determined (see page 11 lines 21-22).” This argument is found to be fully persuasive and the rejection has been withdrawn. With regards to the 35 U.S.C. 102(a)(1) rejection as being anticipated by Schlindwein et al., the grounds for rejection are moot in view of Applicant’s amendment and the rejection has been withdrawn. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1 and 8 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by US 3,972,928. US 3,972,928 discloses the compound PNG media_image1.png 36 170 media_image1.png Greyscale (see column 11), for example, which anticipates a compound of the claims wherein Y3 is O; Y2, Y1 and Y4 are CH; n3 is 0; R15a and R15a are hydrogen; X3 is NR16; R16 is hydrogen; n4 is 1; R15 and R15 are hydrogen; and X4 is a phosphonium cation. Claims 1 and 8 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by FR 1261280 A. FR 1261280 A discloses the compound PNG media_image2.png 58 146 media_image2.png Greyscale (see page 4), for example, which anticipates a compound of the claims wherein Y3 is S; Y2, Y1 and Y4 are CH; n3 is 0; R15a and R15a are hydrogen; X3 is NR16; R16 is hydrogen; n4 is 1; R15 and R15 are hydrogen; and X4 is a quaternary ammonium cation. Claim Objections Claims 6, 7 and 9 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to KRISTIN ANN VAJDA whose telephone number is (571)270-5232. The examiner can normally be reached on Mon-Fri 6:00-4:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James Alstrum-Acevedo can be reached on 571-272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /KRISTIN A VAJDA/Primary Examiner, Art Unit 1622
Read full office action

Prosecution Timeline

Feb 16, 2022
Application Filed
Jun 02, 2025
Non-Final Rejection — §102
Sep 04, 2025
Response Filed
Dec 05, 2025
Final Rejection — §102
Feb 05, 2026
Response after Non-Final Action
Mar 09, 2026
Request for Continued Examination
Mar 16, 2026
Response after Non-Final Action
Mar 18, 2026
Non-Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600712
AMINO-PYRIMIDINE AMIDES
2y 5m to grant Granted Apr 14, 2026
Patent 12600745
PROCESS FOR PREPARING B-[(7a, 1713)-17-HYDROXY-7-[9-[(4,4,5,5,5-PENTAFLUOROPENTYL)SULFINYL]NONYL]ESTRA-1,3,5(10)-TRIEN-3-YL]-BORONIC ACID
2y 5m to grant Granted Apr 14, 2026
Patent 12590094
COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE AND METABOLIC DISORDERS
2y 5m to grant Granted Mar 31, 2026
Patent 12590111
FLAVONOID DERIVATIVE FOR TREATING DENTAL CARIES
2y 5m to grant Granted Mar 31, 2026
Patent 12590093
INDOLO[2',3':3,4]PYRIDO[2,1-B]QUINAZOLINE COMPOUND AND USE THEREOF
2y 5m to grant Granted Mar 31, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
84%
Grant Probability
95%
With Interview (+10.5%)
2y 0m
Median Time to Grant
High
PTA Risk
Based on 1581 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month